130 related articles for article (PubMed ID: 38615592)
21. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
22. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
23. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
24. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.
Lazzeroni M; DeCensi A; Guerrieri-Gonzaga A; Pagan E; Bagnardi V; Macis D; Serrano D; Vingiani A; Bonizzi G; Barberis M; Pruneri G; Wagner S; Gandini S; Viale G; Bonanni B
Mod Pathol; 2020 Jun; 33(6):1065-1077. PubMed ID: 31925342
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
Zeng Y; Gao W; Chen X; Shen K
Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
[TBL] [Abstract][Full Text] [Related]
27. Multi-omics portrait of ductal carcinoma in situ in young women.
Hong R; Cao B; Chen D; Wu W; Luo T; Lv D; Zhang W; Wang S; Shao K
Breast Cancer Res Treat; 2024 Jul; 206(1):105-118. PubMed ID: 38704773
[TBL] [Abstract][Full Text] [Related]
28. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
[TBL] [Abstract][Full Text] [Related]
29. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
[TBL] [Abstract][Full Text] [Related]
30. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma
Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
Clin Cancer Res; 2021 May; 27(10):2861-2867. PubMed ID: 33727261
[TBL] [Abstract][Full Text] [Related]
32. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
[TBL] [Abstract][Full Text] [Related]
33. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
34. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
35. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
36. Immune Escape in Breast Cancer During
Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
[TBL] [Abstract][Full Text] [Related]
37. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
39. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
40. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
Woodard GA; Price ER
AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
